AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
logo

LYRA(Delisted)

Lyra Therapeutics·NASDAQ
--
--(--)
5.52 / 10
Neutral

Analyst coverage is limited to one neutral rating with a 33% historical win rate, reflecting weak consensus. Conversely, fund‑flow metrics are excellent (8.27/10) with positive inflows across all investor sizes, providing strong capital support.

FundamentalSentiment(5.52)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

0%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-08-14
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate33.3%